Free Trial
NASDAQ:AVTE

Aerovate Therapeutics Q4 2023 Earnings Report

Aerovate Therapeutics logo
$12.48 +2.48 (+24.80%)
As of 05/2/2025

Aerovate Therapeutics EPS Results

Actual EPS
-$25.90
Consensus EPS
-$23.80
Beat/Miss
Missed by -$2.10
One Year Ago EPS
N/A

Aerovate Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aerovate Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 25, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Aerovate Therapeutics' Q2 2025 earnings is scheduled for Monday, May 12, 2025

Aerovate Therapeutics Earnings Headlines

Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
See More Aerovate Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aerovate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aerovate Therapeutics and other key companies, straight to your email.

About Aerovate Therapeutics

Aerovate Therapeutics (NASDAQ:AVTE), a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

View Aerovate Therapeutics Profile

More Earnings Resources from MarketBeat